ArticleThe Journal of investigative dermatology2017
Associations of MC1R Genotype and Patient Phenotypes with BRAF and NRAS Mutations in Melanoma.
Open access · greenAbstract read
In one paragraph
Article in The Journal of investigative dermatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 14 citations in OpenAlex.
- The Role of Transcriptional and Atypical Cyclin-Dependent Protein Kinases in Melanoma.Cancers · 2026Review
- Aggregation of melanoma tumour site within Western Australian families.Cancer epidemiology · 2024Article
- Familial Melanoma and Susceptibility Genes: A Review of the Most Common Clinical and Dermoscopic Phenotypic Aspect, Associated Malignancies and Practical Tips for Management.Journal of clinical medicine · 2021Review
- CaAdvances in cancer research · 2020Review
- Germline Variants Impact Somatic Events during Tumorigenesis.Trends in genetics : TIG · 2019Review
- Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes.The Journal of investigative dermatology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 10 institutions in 5 countries.
Nancy E ThomasDepartment of Dermatology, University of North Carolina, Chapel Hill, North Carolina, USA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA. Electronic address: nthomas@med.unc.edu.
Sharon N EdmistonLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Peter A KanetskyDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida, USA.
Klaus J BusamDepartment of Pathology, Memorial Sloan-Kettering Cancer Center, New York, USA.
Anne KrickerSydney School of Public Health, University of Sydney, Sydney, New South Wales, Australia.
Bruce K ArmstrongSydney School of Public Health, University of Sydney, Sydney, New South Wales, Australia.
Anne E CustSydney School of Public Health, University of Sydney, Sydney, New South Wales, Australia; Melanoma Institute Australia, North Sydney, Australia.
Hoda Anton-CulverDepartment of Epidemiology, University of California, Irvine, California, USA.
Stephen B GruberUniveristy of Southern California Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, USA.
Li LuoDepartment of Internal Medicine, University of New Mexico Cancer Center, University of New Mexico, Albuquerque, New Mexico, USA.
Irene OrlowDepartment of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA.
Anne S ReinerDepartment of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA.
Richard P GallagherBritish Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Roberto ZanettiPiedmont Cancer Registry, Centre for Epidemiology and Prevention in Oncology in Piedmont, Turin, Italy.
Stefano RossoPiedmont Cancer Registry, Centre for Epidemiology and Prevention in Oncology in Piedmont, Turin, Italy.
Lidia SacchettoDepartment of Dermatology, University of North Carolina, Chapel Hill, North Carolina, USA; Politecnico di Torino, Turin, Italy.
Terence DwyerGeorge Institute for Global Health, Nuffield Department of Obstetrics and Gynecology, University of Oxford.
Eloise A ParrishLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Honglin HaoDepartment of Dermatology, University of North Carolina, Chapel Hill, North Carolina, USA.
David C GibbsDepartment of Dermatology, University of North Carolina, Chapel Hill, North Carolina, USA; Department of Epidemiology, Emory University, Atlanta, Georgia, USA.
Jill S FrankLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
David W OllilaLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA; Department of Surgery, University of North Carolina, Chapel Hill, North Carolina, USA.
Colin B BeggDepartment of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA.
Marianne BerwickDepartment of Internal Medicine, University of New Mexico Cancer Center, University of New Mexico, Albuquerque, New Mexico, USA.
Kathleen ConwayLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA; Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA.
GEM Study Group
University of North Carolina at Chapel Hill · USMemorial Sloan Kettering Cancer Center · USThe University of Sydney · AUUniversity of New Mexico · USPiedmont Reference Center for Epidemiology and Cancer Prevention · ITMoffitt Cancer Center · USBC Cancer Agency · CAUniversity of California, Irvine · USUniversity of Oxford · GBUniversity of Southern California · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MVirology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5MUSC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4MWOMEN'S CANCERS RESEARCH PROGRAMP30CA118100 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Yolanda Sanchez · 2005 to 2026
$57.1MUNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melissa A. Troester · 2001 to 2026
$36.3MMEDICAL SCIENTIST TRAINING PROGRAMT32GM008169 · NIGMS · EMORY UNIVERSITY · PI GROSS, ROBERT E · 1987 to 2021
$20.3MFAIR Data Competency and Machine Learning Readiness for Biomedical ScientistsK12GM088021 · NIGMS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI REBECCA S. HARTLEY, Diane Lidke · 2009 to 2026
$16.4MMelanoma RAS/BRAF Mutation:Heterogeneity-Risk-PrognosisR01CA112243 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI THOMAS, NANCY E. · 2005 to 2014
$5.4MA MODEL FOR GENETIC SUSCEPTIBILITY: MELANOMAU01CA083180 · NCI · UNIVERSITY OF NEW MEXICO · PI BERWICK, MARIANNE · 1999 to 2003
$5.2MSolar Exposure and Melanoma SurvivalR01CA112524 · NCI · UNIVERSITY OF NEW MEXICO · PI BERWICK, MARIANNE · 2005 to 2009
$2.5MStatistical Strategies for Establishing Etiologic Heterogeneity of TumorsR01CA163251 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BEGG, COLIN B · 2012 to 2015
$1.5MEpidemiologic Parameters of Rare Cancer Risk FactorsR01CA098438 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI BEGG, COLIN B · 2003 to 2005
$839kNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA016086NCI NIH HHS P30 CA118100NCI NIH HHS R01 CA098438NCI NIH HHS R01 CA112243NCI NIH HHS R01 CA112524NCI NIH HHS R01 CA163251NCI NIH HHS U01 CA083180NIEHS NIH HHS P30 ES010126NIGMS NIH HHS K12 GM088021NIGMS NIH HHS T32 GM008169
Abstract
Associations of MC1R with BRAF mutations in melanoma have been inconsistent between studies. We sought to determine for 1,227 participants in the international population-based Genes, Environment, and Melanoma (GEM) study whether MC1R and phenotypes were associated with melanoma BRAF/NRAS subtypes. We used logistic regression adjusted by age, sex, and study design features and examined effect modifications. BRAF
Indexed as
AdultAgedAustraliaFemaleGenotypeGTP PhosphohydrolasesHumansMaleMelanomaMembrane ProteinsMiddle AgedMutationPhenotypeProto-Oncogene Proteins B-rafReceptor, Melanocortin, Type 1Skin NeoplasmsBRAF protein, humanGTP PhosphohydrolasesMembrane ProteinsNRAS protein, humanProto-Oncogene Proteins B-rafReceptor, Melanocortin, Type 1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.